Multiomic characterization of small cell lung cancer: Real‐world insights into therapeutic opportunities
S. Puri(Moffitt Cancer Center), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Stephen V. Liu(Georgetown University), Trudy G. Oliver(Duke University), Gabriel Sica(UPMC Hillman Cancer Center), S. B. Patel(University of Utah), Florian Kocher(Innsbruck Medical University), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Andreas Seeber(Innsbruck Medical University), Abdul Rafeh Naqash(Oklahoma City University), Hassan M. Abu shukair(University of Oklahoma Health Sciences Center), Hossein Borghaei(Fox Chase Cancer Center), Andrew Elliott(Caris Life Sciences (United States)), Kathleen C Kerrigan(University of Utah), Gilberto Lopes(University of Miami), Balazs Halmos(Montefiore Medical Center), Wallace Akerley(University of Utah), Amit A Kulkarni(City of Hope), Hirva Mamdani(Wayne State University)
Cited by 1
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899